References

• Wakeman, S. E., Larochelle, M. R., Ameli, O., Chaisson, C. E., McPheeters, J. T., Crown, W. H., Azocar, F., & Sanghavi, D. M. (2020). Comparative effectiveness of different treatment pathways for opioid use disorder. JAMA Network Open, 3(2), Article e1920622. https://doi.org/10.1001/jamanetworkopen.2019.20622
• David, A. R., Sian, C. R., Gebel, C. M., Linas, B. P., Samet, J. H., Sprague Martinez, L. S., Muroff, J., Bernstein, J. A., & Assoumou, S. A. (2022). Barriers to accessing treatment for substance use after inpatient managed withdrawal (detox): A qualitative study. Journal of Substance Abuse Treatment, 142, Article 108870. https://doi.org/10.1016/j.jsat.2022.108870
• Savinkina, A., Madushani, R. W. M. A., Eftekhari Yazdi, G., Wang, J., Barocas, J. A., Morgan, J. R., Assoumou, S. A., Walley, A. Y., Linas, B. P., & Murphy, S. M. (2022). Population-level impact of initiating pharmacotherapy and linking to care people with opioid use disorder at inpatient medically managed withdrawal programs: An effectiveness and cost-effectiveness analysis. Addiction, 117(9), 2450–2461. https://doi.org/10.1111/add.15879